Nycomed/Micromet (Switzerland) Drug Class: Antibody Mechanism/Technology: Anti-granulocyte macrophage colony-stimulating factor antibody (MT203): therapeutic approach is to reduce undesired proliferation and activation of inflammatory granulocytes and macrophages influencing several pathophysiological pathways. Primary Indication: Multiple Sclerosis, cancer, inflammation and autoimmune diseases Stage: Phase I
